Aller au contenu principal
Accès ouvert déclaré 2026 article

Interindividual Variability in Platelet Aggregation Among Aspirin-treated patients: a Large Retrospective Analysis

0Citations signalées — pas une note de qualité
1Institutions déclarées
1Pays d’affiliation déclarés

Résumé fourni par la source

Interindividual variability in response to aspirin remains a major challenge in antiplatelet therapy. Identification of patients with high (HPR), optimal (OPR) or low platelet reactivity (LPR) remains challenging and may be influenced by both biological and methodological factors, including interlaboratory variability. We report results of a large cohort of aspirin-treated patients to assess the gold standard light transmission aggregometry (LTA). We retrospectively analyzed 3,065 patients treated with aspirin (ASA; 75-150 mg/day) who sequentially underwent LTA assessment using multiple agonists (ADP 2μM, collagen 2 μg/mL, arachidonic acid [AA] 0.75 mM, epinephrine 10μM). Patients were stratified according to AA-induced platelet aggregation using a 16% cut-off (third quartile). Patients with AA >16% showed significantly higher platelet aggregation across all agonists (p<0.0001). However, a substantial proportion of patients with AA ≤16%, consistent with effective COX-1 inhibition, still exhibited high platelet reactivity when stimulated with ADP, epinephrine or collagen. Collagen-induced aggregation was particularly informative in identifying residual platelet reactivity. Sex-related differences were observed, with females showing higher platelet reactivity, especially to ADP and collagen. Platelet reactivity in aspirin-treated patients is highly heterogeneous, with hyper- or hypo-reactive phenotype potentially affecting the safety and efficacy of antiplatelet therapy. AA-induced aggregation alone is insufficient to fully characterize platelet responsiveness. A multiagonist approach, particularly including collagen, may improve identification of patients with residual platelet reactivity and support personalized antiplatelet strategies. These data support ongoing strategies of guided selection of antiplatelet therapy in patients with cardiovascular disease.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Interindividual Variability in Platelet Aggregation Among Aspirin-treated patients: a Large Retrospective Analysis
Date Crossref
01/08/2026
Éditeur
Elsevier BV
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.

Institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Sujets associés

Antiplatelet Therapy and Cardiovascular DiseasesPlatelet Disorders and TreatmentsInflammatory Biomarkers in Disease Prognosis

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.